‘Warm’ Chemo Given Ovarian Cancer Patients Seen to Delay Recurrence in Phase 3 Trial

‘Warm’ Chemo Given Ovarian Cancer Patients Seen to Delay Recurrence in Phase 3 Trial
Results from a recent phase 3 clinical trial show that a specialized type of chemotherapy delivery may delay disease recurrence in newly diagnosed, advanced ovarian cancer patients. The specialized technique, called hyperthermic intraperitoneal chemotherapy (HIPEC), involves warming the chemotherapy to temperatures greater than 42.0°C (107.6°F) and circulating it through the abdominal cavity directly after surgery. In

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *